Shots:

• Pliant to receive $80M including upfront & equity investment and eligible to receive development- regulatory and commercial milestones with royalties on sales. Novartis to get exclusive WW license for Pliant’s PLN-1474 and up to three additional candidates
• Novartis will be responsible for all future development- manufacturing and commercial activities- a post-P-I study of PLN-1474- prior to which Pliant will be responsible for all activities
• PLN-1474 is a pre-clinical candidate that selectively inhibit integrin αVβ1- currently being developed for the treatment of liver fibrosis associated with NASH with its expected IND submission to the US FDA by the year-end 2019

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Straitstimes